

Supplemental Online Content

McEntire CRS, Fletcher A, Toledano M, et al. Characteristics of progressive multifocal leukoencephalopathy associated with sarcoidosis without therapeutic immune suppression. *JAMA Neurol*. Published online April 24, 2023.
doi:10.1001/jamaneurol.2023.0841

eTable. Characteristics of S-PML Patients in Scientific Literature 1955-2022

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable. Characteristics of S-PML Patients in Scientific Literature 1955-2022

Study	Year	Patient	Age at NSO	Sex	Sites of Sarcoidosis Involvement	Post-PML IS	S-PML Latency (Months)	PML Diagnosis	PML Treatment	CD4+ (C/ μ L)	MRI Brain Findings	Location of Lesions	CE	mRS nadir
Christensen	1955	1	59	M	Lung	ND	0	Biopsy	ND	ND	ND	ND	ND	ND
Davies	1973	2	46	M	Lung, spleen, liver	ND	0	ND	ND	ND	ND	ND	ND	6
Rosenbloom	1983	3	59	F	Lung	ND	0	Biopsy	ND	820	Left parieto-occipital	Supra	ND	ND
Elovaara	1989	4	59	F	ND	ND	0	ND	ND	ND	ND	ND	ND	ND
Olindo	2000	5	63	F	Lung, salivary glands	ND	192	Biopsy	ND	ND	L parieto-occipital, splenium of CC	Supra	No	6
Haegelle-Link	2006	6	68	ND	ND	ND	0	ND	ND	ND	ND	ND	ND	ND
De Raedt	2007	7	43	M	Lung, bone marrow, uvea, spleen, thoracic LAD, hilar LAD	CS (4 months)	0	Biopsy	CDF	88	R parietal and occipital	Supra	No	ND
Goldbecker	2010	8	50	F	Lung	CS	240	Biopsy	ND	ND	L fronto-temporal	Supra	No	4
Yagi	2010	9	34	M	Lung, uvea, skin, parotids	CS, CYC	156	Biopsy and CSF	CDF	Normal	R frontal and parietal	Supra	No	ND
Hohlfeld	2012	10	39	M	Lung, spleen, bone marrow, mediastinal LAD	ND	0	CSF	ND	171	R temporal and occipital, R thalamus	Supra	No	ND
Davis	2013	11	ND	F	Lung, heart, mediastinum	ND	0	Biopsy (CSF obtained later)	ND	627	L parieto-occipital and R temporal	Supra	No	ND
Matsudaira	2014	12	60	M	Hepatic and supraclavicular LNs	CS	480	Biopsy	MFQ, MTZ	ND	R frontal and temporoparietal	Supra	ND	3
Jamilloux*	2014	13	41	M	Lung, mediastinum	CS	0	Biopsy	CTB, MTZ	354	ND	ND	No	ND
		14	41	M	Lung, mediastinum	CS	0	Biopsy	CTB, MTZ	354	ND	ND	No	ND

Galdys	2016	15	48	M	Lung, Skin	CS, INF	ND	Biopsy	MTZ	ND	L thalamus, temporal lobe	Supra	No	6
Ellrichmann	2016	16	38	M	Lung, retroperitoneal LAD	CS	0	CSF	MTZ, MFQ, CDF	92	L frontal and parietal	Supra	No	ND
Hellouin	2016	17	77	F	Lung, kidneys, mediastinal LAD	ND	60	CSF	NR	311	L frontal and parietal	Supra	No	3
Scholten	2017	18	57	M	Mediastinum and hilar lymphadenopathy	ND	0	CSF	MTZ	ND	ND	ND	No	6
Gamperl	2018	19	76	F	Lung, mediastinal LAD	ND	24	CSF	MTZ	ND	B/L frontal and temporal lobes	Supra	Yes	3
		20	54	F	Lung	CS, CYC	72	Biopsy	MTZ, MFQ	ND	L frontal, R parietal, B/L occipital	Supra	No	4
		21	63	F	Lung, bone marrow	ND	0	CSF	ND	Decreased	R frontoparietal	Supra	No	6
Alstadhaug	2020	22	78	F	Lung, mediastinum, abdomen	CS	300	CSF	MTZ, rhIL-7	245	B/L subcortical lesions	Supra	No	ND
Elbadri	2020	23	49	M	Lung, uvea, LAD	CS	0	CSF	ND	ND	L parieto-occipital and temporal	Supra	No	6
Guffroy	2020	24	45	M	Lung	CS, HCQ	3	CSF	IL-7	120	L>R frontoparietal	Supra	No	5
Dohrn	2021	25	5th decade	M	ND	CS	0	CSF	MTZ, MFQ	106	L occipital	Supra	No	ND
		26	6th decade	M	ND	CS	ND	Biopsy (CSF obtained later)	MTZ, MFQ	464	R parietooccipital	Supra	No	6
		27	6th decade	M	ND	CS	0	CSF	MTZ, MFQ	404	L frontal and B/L parietal	Supra	No	6
		28	7th decade	F	ND	CS	ND	Biopsy (CSF obtained later)	MTZ, MFQ, CDF	382	R parietal, temporal, occipital	Supra	No	ND

		29	4th decade	M	ND	CS	0	CSF	MTZ, MFQ, CDF	132	L parietal, frontal, occipital	Supra	No	ND
Graf	2021	30	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	6
		31	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Patel	2021	32	35	M	Lung, portal, LNs in left para-aortic and aortocaval regions	CS, MTX	5	ND	MTZ, MFQ, PEM	106	R vermis and cerebellar peduncle, B/L frontoparietal, L temporal	Infra	No	5
Primicerio	2021	33	60	M	ND	CS	ND	ND	MTZ	ND	B/L frontal	Supra	No	6
Rosenkranz	2022	34	48	M	ND	ND	15	Biopsy	IFX	140	Parieto-occipital	Supra	No	ND
		35	49	M	ND	ND	0	Ataxia, dysarthria Apraxia, aphasia	IFX	165	Parieto-occipital	Supra	Yes	Alive
		36	63	M	ND	ND	7	ND	IFX	205	Cerebellum, pons, medulla	Infra	No	Alive
		37	55	M	ND	ND	0	ND	IFX	231	Thalamus, internal capsule, precentral gyrus	Supra	No	Alive

AZA: Azathioprine; B/L: Bilateral; CDF: Cidofovir; CE: Contrast enhancement; CS: Corticosteroids; CTB: Cytarabine; CYC: Cyclophosphamide; HCQ: Hydroxychloroquine; IFX: Infliximab; NSO: Neurologic symptom onset; L: Left; MFQ: Mefloquine; MTX: Methotrexate; MTZ: Mirtazapine; PEM: Pembrolizumab; R: Right

*Four patients were documented as having cerebellar involvement, although unspecified whether they also showed supratentorial involvement.

**Corticosteroids increased 3 months prior to NSO

†Corticosteroids started 3 weeks prior to NSO